The 2026 oral probiotic and topical secretome acne trial protocol tests live oral probiotics plus a topical secretome as add-ons to standard acne care. People with acne-prone skin can ask a dermatologist whether an add-on approach fits their case, what it replaces, and how safety is tracked.
Secretome means the mix of signals secreted by cells, used here as a topical preparation alongside oral probiotics. The protocol was published by Lestari et al. as a phase 2 double-blind randomized trial with four parallel arms including double placebo, according to the published protocol in BMJ Open.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What is the trial actually testing?
- Who fits the study, and how long does it last?
- What does earlier probiotic evidence show?
- Where do these add-ons fit with standard care?
What is the trial actually testing?
The trial does not replace standard therapy. It tests probiotics and secretome as extra layers on top of usual care for acne vulgaris.
The four-arm design separates each add-on effect. Patients receive probiotic plus secretome, probiotic alone, secretome alone, or double placebo. That structure helps show whether benefit comes from one product, the pair, or neither.
Who fits the study, and how long does it last?
The trial plans to enroll 64 patients with mild-to-moderate facial acne. Diagnosis is made by a certified dermatologist using Lehmann lesion-count criteria.
Treatment runs for 8 weeks, within a study period from June 2025 to June 2026. Assessments occur at baseline and after therapy, covering acne severity, fecal microbiome changes, and clinical outcomes.
- Ask whether your acne matches mild-to-moderate facial acne by lesion count
- Ask who made your diagnosis and whether it used the same criteria
- Ask about visit timing, photos, lesion counts, and stool testing
What does earlier probiotic evidence show?
A 2026 review found probiotics had the strongest biotic effect for acne, with large inflammatory and noninflammatory lesion reductions, Medscape reported in the biotics review. Reductions were -88.3% for inflammatory lesions and -47.9% for noninflammatory lesions.
The same review found a nonsignificant trend favoring oral over topical use. That means oral looked better, but the gap could be chance. It does not prove oral probiotics work for every acne type.
Where do these add-ons fit with standard care?
Biotic therapy is not mentioned in the American Academy of Dermatology's January 2024 acne guidelines, MDedge reported in the updated AAD guidelines. Those guidelines give strong recommendations only to benzoyl peroxide, retinoids, antibiotics and combinations, and isotretinoin for severe disease.
No exosome or secretome product has FDA approval for skin use, Dermatology Times reported in their exosome explainer. The FDA treats cell-derived products marketed to treat disease as unapproved drugs or biologics, regardless of marketing claims. AAD guidance also limits routine oral antibiotics for acne to 3-4 months, so ask whether a probiotic or secretome add-on replaces, shortens, or only accompanies topical or antibiotic therapy and what safety checks apply.
You Might Also Like
- Skin Microbiome Outcomes in the 2026 Probiotic Acne Review: Questions People With Acne-Prone Skin Can Ask a Dermatologist
- Probiotics for Acne in a 2026 Systematic Review and Meta-Analysis: Questions People With Acne-Prone Skin Can Ask a Dermatologist
- The 2026 Global Delphi Consensus on Acne and the Microbiome: Questions People With Acne-Prone Skin Can Ask a Dermatologist